Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)
European regulators on Dec. 12 recommended refusing marketing authorization for Anavex’s Alzheimer’s drug Blarcamesine, citing insufficient evidence of effectiveness, unresolved safety issues, and quality concerns. The EMA said Anavex may request re-examination within 15 days. Anavex shares, already volatile, moved sharply in early trading.
